<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy of ovarian cancer in pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy of ovarian cancer in pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chemotherapy of ovarian cancer in pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carolyn D Runowicz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Molly Brewer, DVM, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A gynecologic malignancy is estimated to complicate four to eight of every 100,000 pregnancies [<a href="#rid1">1-4</a>]. Unfortunately, the data on the effects of antineoplastic drugs administered during pregnancy have largely been derived from case reports, small case series, and collected reviews of pregnant women treated for a variety of cancers. There are even less data on long-term outcomes in offspring.</p><p>This topic will address the administration of chemotherapy for women diagnosed with ovarian cancer in pregnancy. In order to optimize treatment outcomes, a pregnant woman with a diagnosis of ovarian cancer should be managed by a multidisciplinary team that includes experts in the fields of maternal-fetal medicine, gynecologic oncology, pediatrics, and pathology. </p><p>The clinical manifestations and diagnosis of ovarian cancer in pregnancy and surgical management of this disease are reviewed separately. (See  <a class="medical medical_review" href="/d/html/3201.html" rel="external">"Adnexal mass: Evaluation and management in pregnancy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Concerns about the administration of cytotoxic chemotherapy during pregnancy arise because chemotherapy preferentially kills rapidly proliferating cells, and the fetus represents a rapidly proliferating cell mass. Individual chemotherapeutic agents have resulted in adverse effects including intrauterine growth restriction, prematurity, and low birth weight in the infants [<a href="#rid5">5</a>]. Chemotherapy may also cause fetal toxicities similar to those observed in the mother (eg, bone marrow suppression).</p><p>The risks of spontaneous abortion, fetal death, and major malformations vary depending on the agent used and the trimester of pregnancy. These risks must be weighed against the benefits of immediate versus delayed (ie, postdelivery) chemotherapy for the mother. Ethical considerations of treatment during pregnancy have emphasized the role of patient autonomy and the concept of beneficence and nonmaleficence for both the mother and fetus [<a href="#rid6">6</a>]. </p><p>Although previous data suggested that the administration of chemotherapy increased the risk of fetal malformations, most data suggest this is not the case. It is now believed that the impact of chemotherapy during pregnancy is predominantly dependent on when treatment is administered:</p><p class="bulletIndent1"><span class="glyph">●</span>During the first four weeks of gestation (first two weeks post conception) the embryo is undifferentiated. Fetal exposure to cytotoxic agents at this point results in "all or none" phenomena: either the pregnancy is lost or it continues with no apparent adverse effect [<a href="#rid5">5,7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Organogenesis occurs during weeks 5 to 10 weeks of gestation. The administration of cytotoxic drugs, particularly antimetabolites (eg, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>) and alkylating agents (eg, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>), during this period carries an increased risk of fetal malformations. In a review of the literature, rates of adverse pregnancy outcomes (APOs) for anti-neoplastic agents in single and combination therapy were 33, 27, and 25 percent for the first, second, and third trimesters. Rates of congenital malformations (included in the APOs) were 16, 8, and 6 percent for the first, second, and third trimesters [<a href="#rid8">8</a>]. The majority of stillborn infants and infants with chromosomal or congenital abnormalities occur when chemotherapy is administered in the first trimester. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When chemotherapy is delivered to the mother during the second and third trimesters of pregnancy, the risk of fetal malformation is lower. First trimester exposure poses a larger and more permanent risk to the fetus. Administration of chemotherapy within three weeks of anticipated delivery or beyond 35 weeks of gestation may induce neonatal myelosuppression and complicate delivery due to adverse effects of treatment on bone marrow reserves. This includes potential complications such as bleeding, sepsis, and death. Additionally, neonatal toxicity may be higher if chemotherapy is administered peripartum because placental drug clearance is generally more effective than either hepatic and/or renal drug clearance in the neonate [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">OVARIAN CANCER DURING PREGNANCY</span><span class="headingEndMark"> — </span>There are several different histologic types of malignancy that can arise within the ovary including epithelial ovarian cancer (EOC), ovarian germ cell tumors, and sex-cord stromal tumors. In some series of women presenting with an ovarian malignancy while pregnant, germ cell tumors predominate, while others report a higher frequency of EOC. The indications and medical treatment of ovarian cancer during pregnancy by histologic type is discussed below. (See  <a class="medical medical_review" href="/d/html/3201.html" rel="external">"Adnexal mass: Evaluation and management in pregnancy", section on 'Malignant neoplasms'</a>.)</p><p class="headingAnchor" id="H84410292"><span class="h1">EPITHELIAL OVARIAN CANCER</span></p><p class="headingAnchor" id="H4"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Following surgery, the indications for adjuvant treatment of epithelial ovarian cancer (EOC) are similar for pregnant and nonpregnant women. However, administration of chemotherapy during the first trimester <strong>should be avoided</strong>. We recommend chemotherapy for:</p><p class="bulletIndent1"><span class="glyph">●</span>Women with early-stage EOC  (<a class="graphic graphic_table graphicRef113545" href="/d/graphic/113545.html" rel="external">table 1</a>) if any of the following high-risk features is present: stage IA/IB, grade 2/3; stage IC or II (any histology); serous or clear cell carcinoma (stage IA, IB, IC, or II) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with stage III or IV EOC </p><p></p><p class="headingAnchor" id="H294838285"><span class="h2">Regimen</span><span class="headingEndMark"> — </span>As with nonpregnant women, we recommend the use of a platinum drug plus taxane for women with EOC in pregnancy because, in general, this combination results in the best survival outcomes. For women diagnosed during pregnancy, we prefer <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> to <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> because it is a better tolerated agent and reduces the risk of long-term side effects (eg, renal and neurotoxicity). Although there are few data to guide the use of taxanes in pregnancy, it has been used to treat breast cancer in pregnancy without apparent adverse events [<a href="#rid10">10-12</a>]. We prefer <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> rather than <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> because it is generally less myelotoxic.</p><p>Targeted therapy has been incorporated into treatment regimens for nonpregnant women, eg, poly(ADP-ribose) polymerase inhibitors, which have the capacity to cross the placenta. Large molecules (for example, monoclonal antibodies) can cross the placenta and reach the fetus after 14 weeks. Animal data has demonstrated potential embryotoxicity and risk of adverse fetal outcomes with these agents  (<a class="graphic graphic_table graphicRef131168" href="/d/graphic/131168.html" rel="external">table 2</a>) [<a href="#rid13">13</a>]. Angiogenesis inhibitors, eg, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, a humanized anti-vascular endothelial growth factor antibody, are teratogenic and induce intrauterine growth restriction, pregnancy loss, and skeletal malformation in animal models [<a href="#rid14">14</a>]. Therefore, these agents should not be used until after delivery.</p><p>All women with EOC in pregnancy should be informed of the limited data on maternal and fetal outcomes associated with treatment. In one of the largest cohort studies of pregnant women with all types of cancer treated at multiple institutions, 84 were exposed to taxanes and 74 were exposed to platinum-based chemotherapy [<a href="#rid15">15</a>]. Both drugs were associated with an increased risk of delivery of a small for gestational age infant: platinum odds ratio (OR) 3.12, 95% CI 1.45-6.70 and taxanes OR 2.07, 95% CI 1.11-3.86. However, it was not possible to determine whether these findings were related to in-utero drug exposure or to other factors, such as effects of other medications, maternal stress, lack of adequate gestational weight gain, and other prenatal factors.</p><p class="headingAnchor" id="H294839653"><span class="h2">Administration</span><span class="headingEndMark"> — </span>Patients can be treated with single agent <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> or a combination of carboplatin and a taxane. A decision should be made on an individual basis taking into account potential risks and benefits of treatment. </p><p class="headingAnchor" id="H294839610"><span class="h3">Intraperitoneal therapy</span><span class="headingEndMark"> — </span>In the absence of a larger experience, we do not administer intraperitoneal (IP) chemotherapy in these patients. There is only one case report of a woman with ovarian cancer treated with IP therapy for four cycles during pregnancy. She underwent a cesarean section at 37 weeks; the baby was male and had bilateral congenital talipes equinovarus [<a href="#rid16">16</a>]. The role of IP therapy for advanced ovarian cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer", section on 'Women with optimally cytoreduced disease'</a>.)</p><p class="headingAnchor" id="H294838311"><span class="h2">Timing of chemotherapy</span></p><p class="headingAnchor" id="H294838341"><span class="h3">Early-stage disease</span><span class="headingEndMark"> — </span>For pregnant women with high-risk, early-stage EOC, we suggest initiation of chemotherapy following completion of the first trimester. The approach is similar to the treatment of nonpregnant women with early-stage EOC. (See <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/d/html/3199.html" rel="external">"Adjuvant therapy of early-stage (stage I and II) epithelial ovarian, fallopian tube, or peritoneal cancer", section on 'Choice of adjuvant treatment'</a>.)</p><p>For women who prefer not to receive treatment during pregnancy due to concerns for fetal safety, it may be reasonable to delay adjuvant chemotherapy until after delivery. The evidence to support this comes from two studies that evaluated the impact of a treatment start delay [<a href="#rid17">17</a>]. In these trials, 271 nonpregnant women with high-risk stage I EOC were randomly assigned treatment with adjuvant <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> versus observation (trial 1) or P-32 (trial 2). In both trials, women who were not treated with cisplatin received cisplatin at the time of relapse. The main results were:</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> reduced the risk of relapse in both trials (compared with observation, hazard ratio [HR] 0.35, 95% CI 0.14-0.89; compared with P-32, HR 0.39, 95% CI 0.19-0.77).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no difference in five year overall survival (88 and 82 percent with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or observation; HR 1.15, 95% CI 0.44-2.98; 81 and 79 percent with cisplatin or P-32; HR 0.72, 95% CI 0.72, 95% CI 0.37-1.43).</p><p></p><p class="headingAnchor" id="H294838374"><span class="h3">Advanced-stage disease</span><span class="headingEndMark"> — </span>Women with advanced disease should begin chemotherapy as soon as they are out of the first trimester and have recovered from surgery. We generally prefer to initiate treatment in two to four weeks after surgery for ovarian cancer. The approach to treatment is similar to that for nonpregnant women with advanced EOC. Although dose-dense (weekly) <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> has been reported to improve progression-free survival, other groups have been unable to duplicate these data [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer", section on 'Women with suboptimally cytoreduced disease'</a> and  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer", section on 'Women with optimally cytoreduced disease'</a>.) </p><p class="headingAnchor" id="H9"><span class="h1">GERM CELL TUMORS</span><span class="headingEndMark"> — </span>Most germ cell ovarian malignancies occur in young women and are limited to one ovary [<a href="#rid3">3</a>]. Maximal surgical cytoreduction is usually undertaken initially. (See  <a class="medical medical_review" href="/d/html/3197.html" rel="external">"Treatment of malignant germ cell tumors of the ovary"</a> and  <a class="medical medical_review" href="/d/html/2952.html" rel="external">"Approach to surgery following chemotherapy for advanced testicular germ cell tumors"</a>.)</p><p>Despite being diagnosed at a relatively early stage, we recommend adjuvant chemotherapy for most women with completely resected malignant ovarian germ cell tumors <strong>except</strong> those with stage IA dysgerminoma  (<a class="graphic graphic_table graphicRef113545" href="/d/graphic/113545.html" rel="external">table 1</a>) or stage I grade one immature teratoma. When indicated, chemotherapy should be delayed at least until completion of the first trimester of pregnancy [<a href="#rid20">20-22</a>]. The most commonly used regimen is <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (BEP  (<a class="graphic graphic_table graphicRef65516" href="/d/graphic/65516.html" rel="external">table 3</a>)). (See  <a class="medical medical_review" href="/d/html/3236.html" rel="external">"Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3197.html" rel="external">"Treatment of malignant germ cell tumors of the ovary"</a>.)</p><p>In other series, use of <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> during pregnancy has been associated with growth restriction and neonatal bone marrow suppression [<a href="#rid5">5,7</a>]. Etoposide is teratogenic in mice and rats at doses much lower than the human dose and should not be used in the first trimester. A consensus report suggested paclitaxel-carboplatin or cisplatin-vinblastine-bleomycin as alternatives to BEP in pregnancy [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Timing of chemotherapy</span><span class="headingEndMark"> — </span>Given that germ cell neoplasms are exquisitely sensitive to platinum-based chemotherapy, several investigators have published case reports addressing a treatment delay until after the completion of the pregnancy [<a href="#rid24">24-26</a>]. A summary of findings is presented below:</p><p class="bulletIndent1"><span class="glyph">●</span>One case report documents a woman with a yolk sac (endodermal sinus) tumor that was surgically resected at 19 weeks of gestation [<a href="#rid24">24</a>]. The pregnancy was allowed to continue and BEP was not initiated until after the baby was delivered at 36 weeks. At a follow-up of 27 months, there was no evidence of recurrence disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another report described a patient with a yolk sac tumor resected at 22 weeks of gestation, after which the pregnancy was allowed to continue [<a href="#rid25">25</a>]. Unfortunately, at 34 weeks she was found to have tumor regrowth. After secondary debulking and delivery of the infant, the mother was successfully treated with BEP and was without evidence of disease 39 months after her last treatment with chemotherapy.</p><p></p><p>These reports suggest that delaying adjuvant chemotherapy may increase the risk of recurrence, although without an apparent risk to long-term recurrence free survival. Given the low quality of the data, however, a decision on the timing of adjuvant chemotherapy for women with a germ cell tumor should take into account the individual circumstances and preferences of the mother.</p><p class="headingAnchor" id="H12"><span class="h1">TUMORS OF LOW MALIGNANT POTENTIAL</span><span class="headingEndMark"> — </span>Tumors of low malignant potential have an excellent prognosis and management is the same as that for nonpregnant patients [<a href="#rid27">27</a>]. In general, treatment is surgical and most patients do not require adjuvant chemotherapy. (See  <a class="medical medical_review" href="/d/html/3181.html" rel="external">"Borderline ovarian tumors"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SEX CORD-STROMAL TUMORS</span><span class="headingEndMark"> — </span>Most of these tumors are limited to one ovary, of low malignant potential and/or slowly progressive. The benefit of postoperative treatment for women with stage 1B to IV disease  (<a class="graphic graphic_table graphicRef113545" href="/d/graphic/113545.html" rel="external">table 1</a>) is unclear and practice is variable. Therefore, we suggest oophorectomy alone for disease diagnosed during pregnancy. The decision for chemotherapy, if any, can be deferred to the postpartum period. (See  <a class="medical medical_review" href="/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H189803895"><span class="h1">BREASTFEEDING</span><span class="headingEndMark"> — </span>Cytotoxic agents may reach significant levels in breast milk and thus breastfeeding while on chemotherapy is generally contraindicated [<a href="#rid28">28</a>]. The United States National Library of Medicine Drugs and Lactation Database (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK501922%2F%3Freport%3Dclassic&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trxbRM9n9k9jxarxPZM5TS5htB9tQgQ%2BhkEZ6u8L6V76cKfsHR1IKbAngeDe8Jfsj0k%3D&amp;TOPIC_ID=3198" target="_blank">LactMed</a>) is an excellent resource for information on transfer of specific drugs into human milk and possible effects on the infant or on lactation, if known. Possible adverse effects include immune suppression, impaired growth, or association with carcinogenesis [<a href="#rid29">29</a>]. We agree with the World Health Organization’s recommendation against nursing while receiving chemotherapy [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H1210997116"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119533.html" rel="external">"Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The development of a gynecologic cancer during pregnancy is a rare event, affecting 4 to 8 pregnancies in 100,000. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risks of chemotherapy administration during pregnancy depend on the specific drugs used and the gestational age of the fetus  (<a class="graphic graphic_table graphicRef131168" href="/d/graphic/131168.html" rel="external">table 2</a>). (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early delivery to avoid fetal exposure to chemotherapy is reasonable provided the fetus is ≥34 weeks of gestation and/or fetal lung maturity can be documented. In this setting, the risks of prematurity are relatively low. (See  <a class="medical medical_review" href="/d/html/3201.html" rel="external">"Adnexal mass: Evaluation and management in pregnancy"</a>.) Prematurity can be associated with impaired cognitive development, and therefore iatrogenic prematurity should be avoided when possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If chemotherapy is indicated, we recommend instituting platinum-based chemotherapy during pregnancy rather than waiting until after delivery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We recommend delaying administration until at least the second trimester in order to minimize the potential for fetal injury (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women with epithelial ovarian cancer in pregnancy, we recommend platinum-based therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Patients should be informed of the limited data on maternal and fetal outcomes associated with platinum and/or taxane therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most women with germ cell tumors, we recommend adjuvant platinum-based combination chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). However, women with stage IA dysgerminomas or stage I grade 1 immature teratomas have a good prognosis. We recommend not treating these patients with chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See  <a class="medical medical_review" href="/d/html/3197.html" rel="external">"Treatment of malignant germ cell tumors of the ovary"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oophorectomy is the standard treatment for tumors of low malignant potential and sex cord stromal tumors diagnosed during pregnancy. These patients should not receive chemotherapy in pregnancy. (See <a class="local">'Sex cord-stromal tumors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Amant F, Brepoels L, Halaska MJ, et al. Gynaecologic cancer complicating pregnancy: an overview. Best Pract Res Clin Obstet Gynaecol 2010; 24:61.</a></li><li><a class="nounderline abstract_t">Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006; 16:8.</a></li><li><a class="nounderline abstract_t">Behtash N, Karimi Zarchi M, Modares Gilani M, et al. Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC Pregnancy Childbirth 2008; 8:3.</a></li><li><a class="nounderline abstract_t">Whitecar MP, Turner S, Higby MK. Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management. Am J Obstet Gynecol 1999; 181:19.</a></li><li><a class="nounderline abstract_t">Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283.</a></li><li><a class="nounderline abstract_t">Theriault R, Hahn K. Management of breast cancer in pregnancy. Curr Oncol Rep 2007; 9:17.</a></li><li><a class="nounderline abstract_t">Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am 2005; 32:627.</a></li><li><a class="nounderline abstract_t">Selig BP, Furr JR, Huey RW, et al. Cancer chemotherapeutic agents as human teratogens. Birth Defects Res A Clin Mol Teratol 2012; 94:626.</a></li><li><a class="nounderline abstract_t">Boulay R, Podczaski E. Ovarian cancer complicating pregnancy. Obstet Gynecol Clin North Am 1998; 25:385.</a></li><li><a class="nounderline abstract_t">Zagouri F, Sergentanis TN, Chrysikos D, et al. Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 2012; 83:234.</a></li><li><a class="nounderline abstract_t">Mir O, Berveiller P, Goffinet F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 2010; 21:425.</a></li><li><a class="nounderline abstract_t">Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol 2012; 23:3016.</a></li><li><a class="nounderline abstract_t">Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol 2019; 30:1601.</a></li><li><a class="nounderline abstract_t">Lambertini M, Peccatori FA, Azim HA Jr. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev 2015; 41:301.</a></li><li><a class="nounderline abstract_t">de Haan J, Verheecke M, Van Calsteren K, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol 2018; 19:337.</a></li><li><a class="nounderline abstract_t">Smith ER, Borowsky ME, Jain VD. Intraperitoneal chemotherapy in a pregnant woman with ovarian cancer. Obstet Gynecol 2013; 122:481.</a></li><li><a class="nounderline abstract_t">Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995; 6:887.</a></li><li><a class="nounderline abstract_t">Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374:1331.</a></li><li><a class="nounderline abstract_t">van der Burg ME, Onstenk W, Boere IA, et al. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. Eur J Cancer 2014; 50:2592.</a></li><li><a class="nounderline abstract_t">Hubalek M, Smekal-Schindelwig C, Zeimet AG, et al. Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma. Arch Gynecol Obstet 2007; 276:179.</a></li><li><a class="nounderline abstract_t">Elit L, Bocking A, Kenyon C, Natale R. An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Gynecol Oncol 1999; 72:123.</a></li><li><a class="nounderline abstract_t">Robova H, Rob L, Hrehorcak M, et al. Endodermal sinus tumor diagnosed in pregnancy: a case report. Int J Gynecol Cancer 2007; 17:914.</a></li><li><a class="nounderline abstract_t">Amant F, Halaska MJ, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer 2014; 24:394.</a></li><li><a class="nounderline abstract_t">Shimizu Y, Komiyama S, Kobayashi T, et al. Successful management of endodermal sinus tumor of the ovary associated with pregnancy. Gynecol Oncol 2003; 88:447.</a></li><li><a class="nounderline abstract_t">Aoki Y, Higashino M, Ishii S, Tanaka K. Yolk sac tumor of the ovary during pregnancy: a case report. Gynecol Oncol 2005; 99:497.</a></li><li><a class="nounderline abstract_t">Rajendran S, Hollingworth J, Scudamore I. Endodermal sinus tumour of the ovary in pregnancy. Eur J Gynaecol Oncol 1999; 20:272.</a></li><li><a class="nounderline abstract_t">Morice P, Uzan C, Gouy S, et al. Gynaecological cancers in pregnancy. Lancet 2012; 379:558.</a></li><li><a class="nounderline abstract_t">Egan PC, Costanza ME, Dodion P, et al. Doxorubicin and cisplatin excretion into human milk. Cancer Treat Rep 1985; 69:1387.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.</a></li><li class="breakAll">World Health Organization. Acceptable medical reasons for use of breast-milk substitutes. WHO Press 2009. http://apps.who.int/iris/bitstream/10665/69938/1/WHO_FCH_CAH_09.01_eng.pdf (Accessed on November 26, 2012).</li></ol></div><div id="topicVersionRevision">Topic 3198 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19740709" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gynaecologic cancer complicating pregnancy: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16445603" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18205951" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411786" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120665" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Use of chemotherapy during human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164043" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of breast cancer in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310676" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chemotherapeutic drugs in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851372" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cancer chemotherapeutic agents as human teratogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9629578" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ovarian cancer complicating pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22907101" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Taxanes for ovarian cancer during pregnancy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887464" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Taxanes for breast cancer during pregnancy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22875836" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31435648" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795021" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Targeted agents for cancer treatment during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29395867" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23884267" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intraperitoneal chemotherapy in a pregnant woman with ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624291" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19767092" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25096168" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342499" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9889045" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635618" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Endodermal sinus tumor diagnosed in pregnancy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24445819" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12648602" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Successful management of endodermal sinus tumor of the ovary associated with pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051324" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Yolk sac tumor of the ovary during pregnancy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475120" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endodermal sinus tumour of the ovary in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22325661" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gynaecological cancers in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4075315" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Doxorubicin and cisplatin excretion into human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533352" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Transfer of drugs and other chemicals into human milk.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
